Jump to content

Wolfgang Patsch

Edit links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Edgar181 (talk | contribs) at 16:18, 12 October 2019 (link (via WP:JWB)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Wolfgang Patsch
Born (1946-08-10) August 10, 1946 (age 78)
Wels
NationalityAustrian
Known foratherosclerosis, metabolism
Scientific career
Fieldsatherosclerosis, metabolism
InstitutionsParacelsus Private Medical University of Salzburg

Wolfgang Patsch (born 10 August 1946, Wels) is an Austrian physician, specialized in internal medicine/laboratory medicine and a professor in the Department of Pharmacology and Toxicology at the Paracelsus Private Medical University of Salzburg. He is known for his work in the fields of atherosclerosis, common metabolic disorders such as obesity, insulin resistance and type-2 diabetes and neurodegenerative disorders.

Biography

Wolfgang Patsch studied medicine at the universities of Innsbruck and Vienna from 1964 to 71. In 1971 he was promoted to doctor of medicine sub auspiciis by the President of Austria in Innsbruck.[1] He received further education in biochemistry at the University of Uppsala 1978 and in site directed mutagenesis in Washington D.C. 1985. Patsch began his career as a resident in the Department of Internal Medicine at the University of Innsbruck in 1971. He obtained his licensure for internal medicine in 1977 and was named assistant professor. Patsch moved to the United States in 1978 to work in the Departments of Medicine and Preventive Medicine at the Washington University in St. Louis, where he obtained his medical licensure for the state of Missouri. From 1982 to 1993 he joined the Department of Medicine at Baylor College of Medicine in Houston, where he moved through the ranks to become full professor in 1990. From 1982 to 93 he was director of the Atherosclerosis Laboratory at Baylor College of Medicine and Houston Methodist Hospital and from 1987 to 1993 also director of the CDC-Cholesterol Reference Laboratory. He was board-certified for internal medicine in 1987 and obtained his medical licensure for Texas in 1988.

Patsch moved back to Austria in 1993 to become chairman of the Department of Laboratory Medicine at the Landeskliniken Salzburg, Austria until 2011. 1998 he was named Außerordentlicher Universitätsprofessor, Austria. Patsch is a cofounder of the Paracelsus Medical University (PMU) of Salzburg. From its conception he was involved in the steering committee and was Dean of Research of the PMU from 2003 to 2006. In 2006 Patsch was named full professor at the PMU and also appointed university professor at the Institute of Laboratory Medicine. Since 2011 he has been a professor in the Department for Pharmacology and Toxicology[2] Patsch headed numerous scientific projects sponsored by the National Institutes of Health (NIH), the American Heart Association, the Austrian Science Fund and the Federal Ministry of Science and Research, Austria.

Scientific contribution

As disturbances in plasma lipid and lipoprotein transport are established risk factors for atherosclerotic diseases such as myocardial infarction and stroke the initial scientific activities of Patsch focused on the characterization of human lipoproteins. Using zonal ultracentrifugation methods developed by Josef R. Patsch (and in collaboration with him), a detailed physical and chemical description of very low-density and high-density lipoproteins was completed.[3][4] The methods of lipoprotein isolation, developed in Innsbruck, were used by Patsch for many clinical studies at Washington University in St. Louis.[5] In the laboratory of Gustav Schonfeld, Patsch used rat liver perfusions and primary rat hepatocyte cultures to determine the effects of diets and hormones such as insulin and thyroid hormone on hepatic lipoprotein biosynthesis.[6][7] These studies were continued at Baylor College of Medicine in Houston in collaboration with W. Strobl and S.M. Soyal.[8][9] In a collaborative effort with Josef R. Patsch and Antonio M. Gotto, the strong predictive value of the magnitude of postprandial lipemia for coronary heart disease was established.[10][11] Patsch was one of the principal investigators of the Atherosclerosis Risk in Communities Study (ARIC) from 1985-94. As atherosclerotic disease is often asymptomatic for many years, knowledge about the quantitative importance of risk factors is essential to effectively manage the disorder and reduce its life-threatening sequels. ARIC investigators ascertained the effect size of numerous established and candidate risk factors in well characterized populations using the intima-media thickness of the common carotid arteries as surrogate marker for atherosclerosis and cardiovascular endpoints as outcomes. Patsch contributed to several research projects that quantified the risk associated with plasma lipoproteins including lipoprotein(a) in the fasting and postprandial state.[12][13] After his return to Austria, Patsch concentrated on genetic and functional aspect of energy metabolism. A main research focus was PGC-1alpha, a transcriptional co-activator that orchestrates several biological programs including mitochondrial biogenesis. Other genetic factors with relevance for obesity, type 2 diabetes and the metabolic syndrome also were studied in collaboration with H. Esterbauer, H. Oberkofler, T. Felder and F. Krempler.[14][15][16] More recently, S.M. Soyal and Patsch discovered brain-specific isoforms of PGC-1alpha which are likely to play a role in neurodegenerative disorders such as Huntington's disease, amyotrophic lateral sclerosis and Parkinson's disease.[17][18]

Apart from his research activities, Patsch contributed to the Sciences as reviewer for numerous medical journals, as organizer of medical congresses and as committee member and/or expert for research support-providing institutions such as NIH, NHLBI and NIDDK, the Swiss National Science Foundation, the Israel Science Foundation, the Netherlands Genomic Initiative, Dutch Ministry of Economic Affairs and the EU.

Academic Memberships

Patsch is a member in the advisory or editorial boards of several scientific magazines:

  • Diabetologia[19] (2003-2005)
  • Current Diabetes Reviews[20] (since 2004)
  • Adipocytes (since 2004)
  • Open General and Internal Medicine Journal OGIM[21] (since 2007)

Honors and awards

  • 1971 Promotion Sub auspiciis Praesidentis of Austria
  • 1974 Unilever award, Vienna
  • 1975/76/94 Hoechst-Stiftung, Innsbruck, Graz and Wien
  • 1979 Ärztekammerpreis, Tirol and Vorarlberg
  • 1987 American Board of Internal Medicine,[22] unter den 2 Prozent besten Prüfungskandidaten
  • 1990/91/94 Österreichpreis der Gesellschaft für Kinder- und Jugendheilkunde
  • 1999 Hans-Wendt-Prize der Salzburger Ärztegesellschaft[23]
  • 1999 Austrian Atherosclerosis Society Prize[24]
  • 2000 Austrian Laboratory Society Prize[25]
  • 2005 Among top 5% recipients of grants distributed by NIH between 1980-2004
  • 2012 Sanofi-Prize, Austria[26]

Publications

PubMed

References

  1. ^ http://www.uibk.ac.at/universitaet/profil/geschichte/sub-auspiciis.html
  2. ^ http://www.pmu.ac.at/universitaet/universitaetsinstitute/pharmakologie/team-und-kontakt.html
  3. ^ Patsch W, Patsch JR, Kostner GM, Sailer S, Braunsteiner H. Isolation of subfractions of human very low density lipoproteins by zonal ultracentrifugation. J Biol Chem. 1978; 253:4911-4915.
  4. ^ Patsch W, Schonfeld G, Gotto AM Jr, Patsch JR. Characterization of human high density lipoproteins by zonal ultracentrifugation. J Biol Chem. 1980;255: 3178-3185.
  5. ^ Goldberg AP, Harter HR, Patsch W, Schechtman KB, Province M, Weerts C, Kuisk I, McCrate MM, Schonfeld G. Racial differences in plasma high density lipoproteins in patients receiving hemodialysis. N Engl J Med. 1983;308:1245-1252.
  6. ^ Patsch W, Franz S, Schonfeld G. Role of insulin in lipoprotein secretion by cultured rat hepatocytes. J Clin Invest. 1983;71:1161-1174.
  7. ^ Patsch W, Tamai T, Schonfeld G. Effect of fatty acids on lipid and apoprotein secretion and association in hepatocyte cultures. J Clin Invest. 1983;72:371-378.
  8. ^ Strobl W, Gorder N, Lin-Lee YC, Gotto AM Jr, Patsch W. Role of thyroid hormones in apolipoprotein A-I gene expression in rat liver. J Clin Invest. 1990;85:659-667.
  9. ^ Soyal SM, Seelos C, Lin-Lee YC, Sanders SR, Gotto AM Jr, Hachey DL, Patsch W. Thyroid hormone influences the maturation of apolipoprotein A-I messenger RNA in rat liver. J Biol Chem. 1995;270:3996-4004.
  10. ^ Patsch JR, Prasad S, Gotto AM Jr, Patsch W. High density lipoprotein2: relationship of the plasma levels of this lipoprotein species to its composition, to the magnitude of postprandial lipemia, and to the activities of lipoprotein lipase and hepatic lipase. J Clin Invest. 1987;80:341-347.
  11. ^ "Patsch JR, Miesenbock G, Hopferwieser T, Muehlberger V, Knapp E, Dunn JK, Gotto AM Jr, Patsch W. Relationship of triglyceride metabolism and coronary artery disease: Studies in the postprandial state. Arterioscler Thromb. 1992;12:1336-1345.
  12. ^ Sharrett AR, Chambless LE, Heiss G, Paton CC, Patsch W. Association of postprandial triglyceride and retinyl palmitate responses with asymptomatic carotid artery atherosclerosis in middle-aged men and women. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol. 1995;15:2122-2129.
  13. ^ "Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, Patsch W. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001;104:1108-1113.
  14. ^ "Esterbauer H, Schneitler C, Oberkofler H, Ebenbichler C, Paulweber B, Sandhofer F, Ladurner G, Hell E, Strosberg AD, Patsch JR, Krempler F, Patsch W. A polymorphism in the UCP2 gene promoter is protective against obesity in middle-aged humans. Nature Genet. 2001;28:178-183.
  15. ^ Oberkofler H, Linnemayr V, Weitgasser R, Xie M, Iglseder B, Krempler F, Paulweber B, Patsch W. Complex haplotypes of the PGC-1α gene are associated with carbohydrate metabolism and type 2 diabetes mellitus. Diabetes 2004;53:1385-1393.
  16. ^ Jais A, Einwallner E, Sharif O, Lu TH, Soyal SM, Neureiter D, Dalgaard K, Gossens K, Martins R, Duvigneau JC, Amann S, Lindroos J, Oberkofler H, Saluzzo S, Müller S, Miller K, Krempler F, Hauser-Kronberger C, Bilban M, Knapp S, Lumeng CN, Patsch W, Wagner O, Pospisilik JA, Esterbauer H. Heme-oxygenase 1 drives metaflammation and insulin resistance in mouse and man. Cell 2014,158:25-40.
  17. ^ Soyal SM, Felder TK, Auer S, Hahne P, Oberkofler H, Witting A, Paulmichl M, Landwehrmeyer GB, Weydt P, Patsch W. A greatly extended PPARGC1A genomic locus encodes several new brain specific isoforms and influences Huntington Disease age-of-onset. Hum Mol Genet. 2012;21:3461-3473.
  18. ^ Eschbach J*, Schwalenstöcker B*, Soyal S*, Bayer Wiesner D, Akimoto C, Nilsson A-C, Birve A, Meyer T, Dupuis L, Danzer K, Andersen PM, Witting A, Ludolph AC, Patsch W, Weydt P. PGC-1α is a male-specific disease modifier of human and experimental amyotrophic lateral sclerosis. Hum Mol Genet 2013;22:3477-3484.
  19. ^ http://www.diabetologia-journal.org/
  20. ^ http://benthamscience.com/journal/index.php?journalID=cdr
  21. ^ http://www.benthamscience.com/open/togmj/
  22. ^ http://www.abim.org/
  23. ^ http://salzburger-aerztegesellschaft.at/
  24. ^ http://www.aas.at/pages.php
  25. ^ http://www.oeglmkc.at/index.htm
  26. ^ http://www.pmu.ac.at/news-archiv/article/sanofi-preis-2013-an-der-paracelsus-medizinischen-privatuniversitaet-ausgeschrieben.html

Retrieved from "https://en.wikipedia.org/w/index.php?title=Wolfgang_Patsch&oldid=920903310"